Q-omics provides the consensus-scored SCN8A profile across patient tissues and cancer cell-line models. SCN8A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SCN8A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SCN8A RNA expression shows 19,073 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, HNSC, and THYM as cancer lineages where SCN8A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCN8A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCN8A survival associations across molecular data types. SCN8A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCN8A RNA expression–survival associations across cancer types. High SCN8A expression shows unfavorable associations in MESO, UCEC and KIRP, but favorable associations in UVM, PAAD and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SCN8A RNA expression.
This table summarizes SCN8A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SCN8A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCN8A shows higher tumor expression in HNSC, LUAD, BLCA, LIHC, KIRC and LUSC. The HNSC box plot shows higher SCN8A RNA expression in tumor versus normal tissue (log2 FC = +0.720, t-test p < 0.001).
This table shows molecular features associated with SCN8A in patient tissues and cancer cell lines. In patient samples, SCN8A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCN8A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
